Sintilimab in combination with anlotinib in advanced NSCLC treated with first-line PD-1 antibodies: An open, single-arm, phase II trial

被引：0

作者：

Jin, Y. ^{[1
]}

Yu, X. ^{[1
]}

Fan, Y. ^{[1
]}

He, X. Q. ^{[1
]}

Lin, C. ^{[1
]}

Hong, W. ^{[1
]}

Gu, C. ^{[1
]}

机构：

[1] Zhejiang Canc Hosp, Dept Thorac Med Oncol, Hangzhou, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.10.572

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

497P

引用

页码：S1656 / S1657

页数：2

共 50 条

[41] Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1-Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial
Xu, Qin
Wang, Junjie
Sun, Yang
Lin, Yibin
Liu, Jing
Zhuo, Yanhong
Huang, Zhangzhou
Huang, Songhua
Chen, Ying
Chen, Li
Ke, Meifang
Li, Li
Li, Zirong
Pan, Junping
Song, Yanwen
Liu, Rongqiang
Chen, Chuanben
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : 1795 - +
[42] Efficacy and safety of sintilimab in combination with anlotinib plus metronomic chemotherapy in advanced triple negative breast cancer (SPACE): Preliminary results of a single-arm, multicenter phase II trial
Li, H.
Zhou, D.
Yv, Z.
Liao, Y.
Huang, J.
Sun, S.
Zheng, F.
Li, B.
Fang, S.
Qiang, L.
Ren, G.
Wang, X.
Baoxuan, Z.
Fan, B.
Zhao, X.
Li, W.
Wang, Z.
Fu, H.
Sun, X.
Shi, Z.
ANNALS OF ONCOLOGY, 2024, 35 : S381 - S381
[43] Efficacy and safety of sintilimab in combination with anlotinib plus metronomic chemotherapy in advanced triple negative breast cancer (SPACE): preliminary results of a single-arm, multicenter phase II trial
Li, Huihui
Tan, Qiaorui
Sun, Shujuan
Zhou, Dongdong
Yu, Bo
Su, Mu
Li, Baojiang
Fang, Shu
Qiang, Ling
Ren, Guohua
Bu, Bing
Yin, Sha
Man, Xiaochu
Qiu, Pengfei
Wang, Xinzhao
Li, Chao
Cao, Fangli
Shao, Qian
Han, Dali
Song, Lihua
Fan, Bingjie
Zhang, Baoxuan
Xu, Liang
Zhao, Xianguang
Liao, Yuqian
Xie, Xuemei
Liu, Lanping
CANCER RESEARCH, 2023, 83 (05)
[44] Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial
Chen, Yajin
Du, Chengyou
Shen, Shunli
Zhang, Wu
Shan, Yunfeng
Lyu, Ang
Wu, Jianhui
Shang, Changzhen
Luo, Xuan
Wei, Jinxing
Xiao, Heng
Qiu, Jianguo
Hua, Yunpeng
Wang, Shutong
Wang, Ting
Dai, Shengjie
Zhang, Shuhao
Xie, Bingying
Wu, Yinghao
Hao, Chunyi
CLINICAL CANCER RESEARCH, 2024, 30 (14) : 2937 - 2944
[45] Efficacy and safety of sintilimab in combination with anlotinib plus metronomic chemotherapy in advanced triple negative breast cancer (SPACE): preliminary results of a single-arm, multicenter phase II trial
Li, Huihui
Zhou, Dongdong
Yv, Zeshun
Liao, Yuqian
Huang, Jie
Sun, Shujuan
Zheng, Fangchao
Li, Baojiang
Fang, Shu
Qiang, Ling
Ren, Guohua
Bu, Bing
Qiu, Pengfei
Wang, Xinzhao
Li, Chao
Cao, Fangli
Shao, Qian
Han, Dali
Song, Lihua
Zhang, Baoxuan
Fan, Bingjie
Xu, Liang
Xie, Xuemei
Zhao, Xianguang
Liu, Lanping
Li, Wanlong
Wang, Zhenbo
Liu, Changmin
Fu, Hui
Sun, Xiao
Shi, Zhiqiang
Li, Fengxiang
CANCER RESEARCH, 2024, 84 (09)
[46] Safety and Efficacy of Sintilimab and Anlotinib as First Line Treatment for Advanced Hepatocellular Carcinoma (KEEP-G04): A Single-Arm Phase 2 Study
Chen, Xiaofeng
Li, Wei
Wu, Xiaofeng
Zhao, Fengjiao
Wang, Deqiang
Wu, Hao
Gu, Yanhong
Li, Xiao
Qian, Xiaofeng
Hu, Jun
Li, Changxian
Xia, Yongxiang
Rao, Jianhua
Dai, Xinzheng
Shao, Qianwen
Tang, Jie
Li, Xiangcheng
Shu, Yongqian
FRONTIERS IN ONCOLOGY, 2022, 12
[47] Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC)
Besse, B.
Johnson, M.
Jaenne, P. A.
Garassino, M.
Eberhardt, W. E. E.
Peters, S.
Toh, C. K.
Kurata, T.
Li, Z.
Kowanetz, M.
Mocci, S.
Sandler, A.
Rizvi, N. A.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S717 - S718
[48] Update results of anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase II clinical trial
Hong, G.
Meng, X.
Yang, X.
Zhang, Z. Y.
Xia, J.
Chen, Y-F.
Wu, T.
Shan, Z.
Fan, Q.
Wang, F.
ANNALS OF ONCOLOGY, 2023, 34 : S861 - S861
[49] Anlotinib plus TQB2450 (PD-L1 blockade) combined with nab-paclitaxel and cisplatin as first-line treatment for advanced biliary tract cancer: A single-arm, open-label phase II clinical trial
Jin, Shui-Ling
Qiao, Shishi
Li, Ren-Feng
Zhang, Weijie
He, Wei
Su, Chang
Li, Lu-Hao
Pan, Jie
Guo, Wen-Zhi
Zong, Hong
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 498 - 498
[50] Efficacy and safety of Anlotinib in combination with gemcitabine and cisplatin as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A single-arm clinical trial
Xiao, Zhehao
Chen, Weiling
Du, Youqin
Zeng, Fanyan
Su, Fang
Huang, Shiting
Qu, Song
INTERNATIONAL JOURNAL OF CANCER, 2025,

← 1 2 3 4 5 →